A Modified Approach to the Adoptive Immunotherapy of Walker-256 Carcinosarcoma With a Combination of Activated Macrophages and Photodynamic Therapy

Abstract

Experiments were performed on five batches of Wistar inbred rats with Walker-256 carcinoma receiving sole (PDT, MAK) or combined therapy (PDT+MAK-A; PDT+MAK-B); the control batch (HBSS) consisted of animals with untreated tumors. The results were as follows: (a) the sole treatment (PDT, MAK) gave survival rates between 37.7 and 47.5 %, the "combined" therapy in five doses increased significantly (70.8 %) the survival rate of tumor bearing rats as well as the rate of complete regression (82.1%). The cell-mediated immunity test and histopathological and as well as the electron microscopy observation were in full agreement with the results above. Summing up, this results demonstrate that "combined" photodynamic therapy with intra and peritumoral MAK infusion stimulated cell-mediated antitumoral activity, increased survival rates and reduces incidence of Walker-256 carcinoma in rat model.

Cisplatin primes murine peritoneal macrophages for enhanced expression of nitric oxide, proinflammatory cytokines, TLRs, transcription factors and activation of MAP kinases upon co-incubation with L929 cells

“…Activation of macrophages has been an attractive approach in the development of cancer therapy (Dima et al, 2001;Chen et al, 2002;Thiounn et al, 2002). Many studies have shown that activated macrophages selectively lyse tumor cells in vitro (Fan et al, 2002;Chen et al, 2003) and play an important role in the immune-mediated destruction of tumor cells in vivo (Bonnotte et al, 2001;Tsung et al, 2002).…”

Approaches to improve photodynamic therapy of cancer

“…Adoptive transfer of normal and geneticallymodified immune cells has been shown to be effective in some cases of cancer immunotherapy. Apart from the obvious effectiveness of lymphocytes isolated from PDTcured rats against the same tumor cells growing in syngeneic animals (110), there are also examples of efficient improvement of PDT outcome with intratumoral injection of immature dendritic cells (111)(112), modified human natural killer (NK) cells expressing IL-2 (113), or activated macrophages (114). Interestingly, immune cells delivered to PDT-treated tumor site have been shown to retain their viability and functionality, and improved PDT cure rate in several models utilizing different photosensitizers.…”